In addition, the combination showed significant advantages in other outcome indicators after treatment: E2, P, CA-125, CA-199, MMP-2, MMP-9, Gal-3, VEGF, cyst size, and VAS were significantly lower in patients on the combination than in those on the drugs alone. The gene discussed is MUC16; the disease is cyst.